CA2130563C - Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3 - Google Patents

Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3

Info

Publication number
CA2130563C
CA2130563C CA002130563A CA2130563A CA2130563C CA 2130563 C CA2130563 C CA 2130563C CA 002130563 A CA002130563 A CA 002130563A CA 2130563 A CA2130563 A CA 2130563A CA 2130563 C CA2130563 C CA 2130563C
Authority
CA
Canada
Prior art keywords
treatment
pharmaceutically acceptable
compound
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002130563A
Other languages
English (en)
Other versions
CA2130563A1 (fr
Inventor
Maurice W. Gittos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of CA2130563A1 publication Critical patent/CA2130563A1/fr
Application granted granted Critical
Publication of CA2130563C publication Critical patent/CA2130563C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ester d'octahydro-3-hydroxy-2,6-méthano-2H-quinolizine-8-ylique (I) de l'acide 5-chloro-2, 3-dihydro-2,2-diméthylbenzofurane-7-carboxylique, un nouvel antagoniste du récepteur 5-HT3, son mode de préparation et son application finale dans le traitement des nausées et vomissements chimio-induits, de la douleur associée à la migraine, des troubles cognitifs, des psychoses endogènes hallucinatoires du type dont souffrent les patients atteints de manie et de schizophrénie et dans le traitement du syndrome du côlon irritable et de la toxicomanie.
CA002130563A 1992-02-24 1993-02-03 Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3 Expired - Lifetime CA2130563C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400474.0 1992-02-24
EP92400474 1992-02-24

Publications (2)

Publication Number Publication Date
CA2130563A1 CA2130563A1 (fr) 1993-09-02
CA2130563C true CA2130563C (fr) 1997-11-11

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002130563A Expired - Lifetime CA2130563C (fr) 1992-02-24 1993-02-03 Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3

Country Status (14)

Country Link
EP (1) EP0628043A1 (fr)
JP (1) JPH07504192A (fr)
KR (1) KR100287933B1 (fr)
AU (1) AU675060B2 (fr)
CA (1) CA2130563C (fr)
FI (1) FI105917B (fr)
HU (1) HU216831B (fr)
IL (1) IL104821A (fr)
MX (1) MX9300948A (fr)
NO (1) NO943101D0 (fr)
NZ (1) NZ249346A (fr)
TW (1) TW226374B (fr)
WO (1) WO1993017019A1 (fr)
ZA (1) ZA931146B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048597A1 (fr) 1999-02-18 2000-08-24 Novartis Ag Utilisation systemique d'antagonistes du recepteur 5-ht3 contre des processus inflammatoires rhumatismaux
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329932B1 (fr) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Utilisation des dérivés de la quinolizine et de la quinolizinone pour la manufacture des médicaments
EP0517984A1 (fr) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivés d'analogues d'amide de quinolizines à pont méthano

Also Published As

Publication number Publication date
IL104821A0 (en) 1993-06-10
NO943101L (no) 1994-08-23
MX9300948A (es) 1993-08-01
AU675060B2 (en) 1997-01-23
WO1993017019A1 (fr) 1993-09-02
EP0628043A1 (fr) 1994-12-14
NZ249346A (en) 1995-10-26
CA2130563A1 (fr) 1993-09-02
HU216831B (hu) 1999-09-28
IL104821A (en) 1997-01-10
FI943872L (fi) 1994-08-23
FI105917B (fi) 2000-10-31
ZA931146B (en) 1993-09-14
FI943872A0 (fi) 1994-08-23
HUT68249A (en) 1995-06-28
KR100287933B1 (ko) 2001-05-02
KR950700297A (ko) 1995-01-16
HU9402436D0 (en) 1994-10-28
AU3603493A (en) 1993-09-13
NO943101D0 (no) 1994-08-23
JPH07504192A (ja) 1995-05-11
TW226374B (fr) 1994-07-11

Similar Documents

Publication Publication Date Title
US5011846A (en) Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5718912A (en) Muscarine agonists
EP0920438B1 (fr) Derives d'adenosine a substitution heterocyclique n6
US5342845A (en) Indole derivatives and drugs
EP0518767B1 (fr) Dérivés d'analogues amide de certaines quinolizines méthano-pontés
EP0375726A1 (fr) Composes analogues de la melatonine
DE69330272T2 (de) 4-imidomethyl-1-[2'-phenyl-2-oxoethyl]-piperidine als serotonin-5ht2-antagonisten, ihre herstellung und therapeutische anwendung
IE83573B1 (en) Derivatives of amide analogs of certain methano bridged quinolizines
CA2130563C (fr) Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3
US5955470A (en) Derivatives of amide analogs of certain methano bridged quinolizines
US5508287A (en) 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
EP0507637A2 (fr) Utilisation de carboxamides benzobicycliques pour la fabrication d'un médicament pour l'utilisation comme analgésique
EP0330824A1 (fr) Utilisation des dérivés de la quinolizine et de la quinolizinone pour la manufacture de médicaments pour le traitement de l'arythmie cardiaque
CZ286649B6 (cs) 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano-/2,3-e/indol-8-onové deriváty a farmaceutický prostředek s jejich obsahem
DK175643B1 (da) Anvendelse af quinolizin- og quinolizinon-derivater ved fremstilling af lægemidler
US5258384A (en) S-11-hydroxy-10-methylaporphine and its biologically active salt forms as 5HT1A inhibitors
EP0329903A1 (fr) Utilisation des dérivés de quinolizinone et de la quinolizine pour la manufacture des médicaments pour le traitement du glaucome
US5910501A (en) Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolozin-3(4H)-one and related compounds for treating cognitive disorders
US5106857A (en) N-(1-methyl-3-pyrrolidinyl)-1-(phenylmethyl)-1H-benzimidazol-2-amine and analogs as antiarrhythmic and muscle relaxing agents
FR2609715A1 (fr) Nouveaux diazepinoindoles, leur preparation et leur utilisation comme medicaments
EP0329904A1 (fr) Utilisation des dérivés de la quinolizine et de la quinolizinone dans la manufacture des médicaments pour le traitement de l'anxiété
US5945118A (en) Indole derivative for the treatment of migraine
EP0329905A1 (fr) Utilisation des dérivés de la quinolizine et de la quinolizinone pour la manufacture des médicaments pour l'augmentation de la motilité gastrique
JPH05230057A (ja) 光学活性インダゾール―３―カルボキサミド誘導体及びそれを有効成分とする制吐剤
JPH08503448A (ja) ５ｈｔ▲下１▼▲ａ▼受容体アゴニストによる不随意運動の処置

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20130204